Mr. Mehdi Heidari Horestani | Cancer Genetics | Best Researcher Award

Publications

H2AJ Is a Direct Androgen Receptor Target Gene That Regulates Androgen-Induced Cellular Senescence and Inhibits Mesenchymal Markers in Prostate Cancer Cells

  • Authors: Mehdi Heidari Horestani, Golnaz Atri Roozbahani, Aria Baniahmad
  • Journal: Cancers
  • Year: 2025

The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and-agonist to stimulate growth of target cells

  • Authors: Golnaz Atri Roozbahani, Miriam Kokal-Ribaudo, Mehdi Heidari Horestani, Thanakorn Pungsrinont, Aria Baniahmad
  • Journal: Cell Communication and Signaling
  • Year: 2024

The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer

  • Authors: Mehdi Heidari Horestani, Golnaz Atri Roozbahani, Aria Baniahmad
  • Journal: Journal of Experimental & Clinical Cancer Research
  • Year: 2024

The oncogenic lncRNA MIR503HG suppresses cellular senescence counteracting supraphysiological androgen treatment in prostate cancer

  • Authors: Julia Kallenbach, Mahdi Rasa, Mehdi Heidari Horestani, Golnaz Atri Roozbahani, Katrin Schindler, Aria Baniahmad
  • Journal: Journal of Experimental & Clinical Cancer Research
  • Year: 2024

Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence

  • Authors: Mehdi Heidari Horestani, Katrin Schindler, Aria Baniahmad
  • Journal: Cell Communication and Signaling
  • Year: 2024

Mr. Miguel Garcia-de la Virgen | Oncology | Best Researcher Award

Mr. Miguel Garcia-de la Virgen | Oncology | Best Researcher Award

Miguel Garcia-de la Virgen at IVC Evidensia – AĂșna Especialidades Veterinariass, Spain

Profiles

Orcid

Summary

Mr. Miguel Garcia de la Virgen is a skilled veterinary oncologist with extensive experience in cancer treatment for animals. A resident of the European College of Veterinary Internal Medicine (ECVIM-CA), he is committed to advancing veterinary oncology through research and clinical practice.

Education

  • General Practitioner Certificate in Oncology (2014-2015) – European School of Veterinary Postgraduate Studies (ESVPS), Madrid
  • Master’s in Clinical Oncology (2013-2014) – AsociaciĂłn Española de Veterinaria Aplicada (AEVA), Madrid
  • Veterinary Degree (2007-2012) – University of Zaragoza, Spain.

đŸ’ŒÂ Professional Experience

  • Oncology Resident (2018-2020) – Hospital Veterinario AĂșna Especialidades Veterinarias, Paterna, Valencia
  • Oncology Team Member (2016-2018) – Hospital Veterinari Montjuic, Barcelona
  • General Internship (2015-2016) – Hospital ClĂ­nic Veterinari, Universitat AutĂČnoma de Barcelona
  • First Opinion Veterinary Clinician (2012-2015) – ClĂ­nica Veterinaria OrdĂĄs, AlgemesĂ­, ValĂšncia

🔬 Research Interests

  • Miguel focuses on innovative cancer treatments, clinical trials, and improving oncological care in veterinary medicine.

 

Publications

Impact of Toceranib Phosphate and Carprofen on Survival and Quality of Life in Dogs with Inflammatory Mammary Carcinomas

  • Authors: Miguel Garcia-de la Virgen, Isabel Del Portillo Miguel, Elisa Maiques, Ignacio PĂ©rez Roger, Enric Poch, Juan Borrego
  • Journal: Veterinary Sciences
  • Year: 2024

Clinical and genomic features of Listeria monocytogenes‐associated mesenteric lymphadenitis in a cat

  • Authors: Miguel Garcia-de la Virgen, Inmaculada LĂłpez‐Almela, Alexandra Moura, Sergio VĂĄzquez, Sara Perez‐Montagud, Alexandre Leclercq, Marc Lecuit, Juan J Quereda
  • Journal: Journal of Veterinary Internal Medicine
  • Year: 2024